Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Latest Information Update: 29 Oct 2021
Price :
$35 *
At a glance
- Drugs PM 00104 (Primary)
- Indications Cervical cancer; Endometrial cancer; Zollinger-Ellison syndrome
- Focus Pharmacogenomic; Therapeutic Use
- 27 Jul 2009 Status changed from not yet recruiting to recruiting, as reported in a PharmaMar media release.
- 22 May 2009 New trial record